Vivo Bio Tech Ltd
BSE:511509
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (8.2), the stock would be worth ₹26.45 (7% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.8 | ₹28.49 |
0%
|
| 3-Year Average | 8.2 | ₹26.45 |
-7%
|
| 5-Year Average | 8.5 | ₹27.57 |
-3%
|
| Industry Average | 23.2 | ₹75.1 |
+164%
|
| Country Average | 23.3 | ₹75.24 |
+164%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
V
|
Vivo Bio Tech Ltd
BSE:511509
|
629.6m INR | 8.8 | 13.9 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
303.9B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 3 537.2 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.5B ZAR | 14.4 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.1B USD | -18 026.5 | 38 496.8 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
61.5B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
35.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.7B EUR | 67.3 | 175.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
38.1B USD | -746.1 | -3 496.4 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.3B ZAR | 17.7 | 7 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 15.7 |
| Median | 23.3 |
| 70th Percentile | 34.7 |
| Max | 48 145.1 |
Other Multiples
Vivo Bio Tech Ltd
Glance View
Vivo Bio Tech Ltd. engages in the provision of drug development and discovery services. The company is headquartered in Hyderabad, Telangana. The firm provides services of in-vitro, in-vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. The firm's services are offered to pharma, biotech and Agri companies, which include molecular biology services, the fermentation process of E.Coli harboring the plasmid containing the gene of interest, protein purification, bioassay, Physico-chemical and biochemical/immunological characterization of various proteins. The firm's In-vivo services provide preclinical testing services in rodents/non-rodents, and canines. The firm's subsidiaries include Vivobio Labs Private Ltd, Vivobio Discovery services Private Ltd, Surlogic Life Consultancy Private Ltd and Vivobio Consulting Services Private Ltd.
